(NAMC) - Allergan Inc. (NYSE:AGN) has received an approvable letter from the U.S. Food and Drug Administration for COMBIGAN 0.2%/0.5% for the reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

The approvable letter that they received outlines the remaining conditions that the company must meet in order to obtain FDA final marketing approval.  Allergan plans on working diligently with the FDA to overcome any potential issues.

NAMC Newswire

NAMC Newswire Note: The 2007 "Wall Street to Main Street" Contest is underway and is only  available to subscribers. Keep in mind that all subscriptions are free, all that you need to do is go to www.namcnewswire.com/contest and add your email address, its simple, quick and FREE. You can win one of the many prizes being offered from an iPod, Zune to various gift cards from select retailers..

Wall Street to Main Street is also one of the leading shows on StreetIQ , the leader in financial podcast: http://www.streetiq.com/dir/NAMC.shtml

Also be sure to listen to the "Wall Street to Main Street" radio show that is syndicated daily. Just visit the NAMC radio at www.namcnewswire.com/namcradio.